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Abstract
Introduction: SNPs rs2981582 and rs2981578, located in a linkage disequilibrium block (LD block) within intron 2
of the fibroblast growth factor receptor 2 gene (FGFR2), are associated with a mildly increased breast cancer risk.
Allele-specific regulation of FGFR2 mRNA expression has been reported previously, but the molecular basis for the
association of these variants with breast cancer has remained elusive to date.
Methods: mRNA levels of FGFR2 and three fibroblast growth factor genes (FGFs) were measured in primary fibroblast
and epithelial cell cultures from 98 breast cancer patients and correlated to their rs2981578 genotype. The
phosphorylation levels of downstream FGFR2 targets, FGF receptor substrate 2a (FRS2a) and extracellular signal-
regulated kinases 1 and 2 (ERK1/2), were quantified in skin fibroblasts exposed to FGF2. Immunohistochemical markers
for angiogenesis and lymphocytic infiltrate were semiquantitatively assessed in 25 breast tumors.
Results: The risk allele of rs2981578 was associated with increased FGFR2 mRNA levels in skin fibroblasts, but not in
skin epithelial cell cultures. FGFR2 mRNA levels in skin fibroblasts and breast fibroblasts correlated strongly in the
patients from whom both cultures were available. Tumor-derived fibroblasts expressed, on average, eight times
more FGFR2 mRNA than the corresponding fibroblasts from normal breast tissue. Fibroblasts with higher FGFR2
mRNA expression showed more FRS2a and ERK1/2 phosphorylation after exposure to FGF2. In fibroblasts, higher
FGFR2 expression correlated with higher FGF10 expression. In 25 breast tumors, no associations between breast
tumor characteristics and fibroblast FGFR2 mRNA levels were found.
Conclusions: The influence of rs2981578 genotypes on FGFR2 mRNA expression levels is cell type-dependent.
Expression differences correlated well with signaling levels of the FGFR2 pathway. Our results suggest that the
increased breast cancer risk associated with SNP rs2981578 is due to increased FGFR2 signaling activity in stromal
fibroblasts, possibly also involving paracrine FGF10 signaling.
Introduction
Several genome-wide association studies have shown
that the minor allele of SNP rs2981582, located in
intron 2 of the fibroblast growth factor receptor 2 gene
(FGFR2), is associated with increased breast cancer risk
[1-6]. The odds ratios (ORs) for this SNP are 1.23 in
heterozygotes and 1.63 in homozygotes for the minor
allele [1,2], but attributable risk is high because of the
high frequency of the risk allele population. Fine-scale
genetic mapping and resequencing of the region sur-
rounding rs2981582 resulted in the identification of up
to eight variants in a linkage disequilibrium block (LD
block) within intron 2 of FGFR2 most strongly asso-
ciated with increased breast cancer risk, including SNP
rs2981578 [1,5,7]. The location of this LD block suggests
that these variations somehow modify the functioning of
FGFR2.
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LD block, one of them being rs2981578, alter the DNA
binding affinity of octamer-binding transcription factor
1 (Oct-1), runt-related transcription factor 2 (Runx2)
and CCAAT/enhancer binding protein b (C/EBPb).
Accordingly, increased expression of FGFR2 mRNA was
observed in total RNA isolated from breast tumors of
patients homozygous for the risk allele as compared to
homozygotes for the major allele [7]. Paradoxically, Sun
et al. [8] recently reported decreased expression of
FGFR2 mRNA in normal breast tissue of homozygotes
for the risk allele.
FGFR2 is one of five fibroblast growth factor (FGF) recep-
tors known in humans to be involved in various signaling
pathways that regulate process e ss u c ha sc e l lg r o w t h ,a p o p -
tosis and differentiation. Two isoforms, FGFR2-IIIb and
FGFR2-IIIc, are the result of mutually exclusive alternative
splicing of exon 9 or 10 of FGFR2. Isoform IIIb is present
on epithelial cells and binds ligands FGF3, FGF7, FGF10
and FGF22 and isoform IIIc is present on mesenchymal
cells and binds FGF2, FGF4, FGF6, FGF9, FGF17 and
FGF18 [9]. Binding of a ligand to the receptor can activate
several signaling pathways, including the mitogen-activated
protein kinase (MAPK) pathway [10,11].
Downregulation of FGFR2 protein has been reported in
up to 67% of breast tumors [12], whereas amplification of
FGFR2 and upregulation of FGFR2 mRNA expression
have been reported in less than 10% of breast tumors
[10,13]. Somatic FGFR2 mutations are rare in breast can-
cer [14]. A switch from the IIIb to the IIIc isoform in
tumor cells, resulting in activation of the receptor by
other FGFs, has been reported in a subset of prostate
cancers and in a few breast cancer cell lines [15-17].
To further unravel the mechanisms by which the SNPs
in intron 2 of FGFR2 increase breast cancer risk, and to
address the heterogeneous cellular composition of breast
tumors, we studied the expression of FGFR2 mRNA in
relation to the rs2981578 genotype in fibroblasts and
epithelial cells cultured from breast tissue. We also com-
pared the FGFR2 mRNA expression in fibroblasts derived
from normal skin tissue, normal breast tissue and breast
tumor tissue. Furthermore, we explored the functional
implications of different levels of FGFR2 expression at the
cellular level by studying the downstream MAPK pathway.
Finally, we compared histological characteristics between
tumors of patients with high and low FGFR2 levels.
Materials and methods
Patients
Breast tissue was obtained from 98 women who had
undergone breast cancer-related surgery at the Leiden
University Medical Center (LUMC) from February 2006
until December 2010 (patient demographics are given in
Table 1). According to the Dutch Medical Treatment
Act, anonymized samples obtained during medical treat-
ment may be used in medical research if the patient
does not object to this “secondary use” (opt-out system).
Samples were coded in such a way that identifying infor-
mation was not accessible by the researcher, but sam-
ples still could be linked to pathology reports by
authorized clinicians. The use of residual material for
this study was approved by the Department of Pathology
of the LUMC (code OP 25-06). The study protocol was
compliant with the Code of Conduct issued by the
Dutch Federation of Medical Scientific Societies.
Tissue culture
Fibroblasts and epithelial cells were cultured separately
from skin tissue, normal breast tissue or tumor tissue by
cutting the tissue patches into 2-mm × 2-mm pieces.
Tissue patches were allowed to attach to the culture
flask for 30 minutes, then we added DMEM/F12 med-
ium (1:1 dilution; GIBCO/Invitrogen, Breda, the Nether-
lands) supplemented with 20% FCS (Bodinco, Alkmaar,
The Netherlands) and antibiotics. Cells were grown at
37°C in 5% CO2. Each fibroblast culture was expanded
in medium supplemented with 10% FCS and antibiotics.
Epithelial cells were grown in HuMEC Ready Medium
(GIBCO/Invitrogen) or in DermaLife K Serum-Free Ker-
atinocyte Culture Medium (Lifeline Cell Technology,
Walkersville, MD, USA) (see also Table 2). The mor-
phology of primary cultures was in agreement with the
morphology of established epithelial and mesenchymal
cell lines (Figure S1 in Additional file 1).
Genotyping
Genomic DNA was isolated using the Wizard Genomic
DNA Purification Kit (Promega, Leiden, The Netherlands)
according to the manufacturer’s instructions. Four SNPs
in intron 2 of FGFR2 were genotyped (Table 3).
Table 1 Characteristics of the patient cohort
a
Characteristics Data
Total number of patients 98
BRCA1/2 mutation carriers, n (%) 10 (10%)
Diagnosis
Mean age at diagnosis
b, years
(±SD)
55 (±14)
Invasive breast cancer, n 83
In situ breast cancer, n 8
Prophylactic surgery, no cancer,
n
7
Tumor characteristics (n = 91)
ER status 54 positive, 20 negative, 17
unknown
aSD: standard deviation; ER: estrogen receptor.
bAge at diagnosis of breast
cancer. The seven patients who underwent prophylactic surgery were
excluded from this analysis.
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Total RNA was isolated from exponentially growing
fibroblasts or epithelial cells using NucleoSpin RNA II
Kit (Clontech, St-Germain-en-Laye, France) according
to the manufacturer’s instructions. During isolation, a
30-minute DNase treatment was performed to ensure
complete degradation of contaminating DNA.
A detailed description of the RT reaction and quantita-
tive PCR (qPCR) conditions can be found in the supple-
mentary methods section (Additional file 2). Briefly, qPCR
was performed to analyze the expression of a specific gene
(Table 4) using the Bio-Rad iCycler thermal cycler and the
iQ SYBR Green Supermix (Bio-Rad Laboratories, Her-
cules, CA, USA) according to the manufacturer’s recom-
mendations. Each gene was measured at least twice in
each sample. As reference genes, the TATA box binding
protein (TBP) and heterogeneous nuclear ribonucleopro-
tein M (HNRPM or HNRNPM) (fibroblasts) genes or sig-
nal recognition particle receptor (SRPR), HNRPM and
TBP (epithelial cells) genes were used.
Fragment analysis
Isoforms FGFR2-IIIb and FGFR2-IIIc differ by the alter-
native splicing in of either exon 9 or exon 10 into the
mature mRNA, resulting in a difference of 3 bp in
length of the mature mRNA. A PCR fragment of 297 bp
for FGFR2-IIIb or 300 bp for FGFR2-IIIc mRNA was
amplified by PCR with 38 cycles and an annealing tem-
perature of 70°C using the 6-carboxyfluorescein-labeled
forward primer 5’-GTGGAAAAGAACGGCAGTAAA-
TACG-3’ and reverse primer 5’-CACCATACAGGC-
GATTAAGAAGACC-3’ located in exons 8 and 11.
Fragment analysis was performed on cDNA from 14
skin epithelial cell cultures and 52 skin fibroblast cul-
tures using the 3730xl DNA Analyzer (Applied Biosys-
tems, Carlsbad, CA, USA) and the GeneScan 400HD
ROX Size Standard (Applied Biosystems).
Measuring FGFR2 protein levels
FGFR2 protein levels were analyzed in seven exponen-
tially growing fibroblast cultures with high (n =3 )o r
Table 2 Culture medium used to culture skin epithelial
cells
a
Culture ID Medium used
46 HuMEC
47 HuMEC
52 HuMEC
54 HuMEC
55 HuMEC
57 HuMEC
58 HuMEC
59 HuMEC
64 HuMEC
65 HuMEC
69 DermaLife
70 DermaLife
77 DermaLife
83 HuMEC
100 HuMEC
103 DermaLife
132 DermaLife
140 DermaLife
143 DermaLife
152 DermaLife
157 DermaLife
163 DermaLife
170 DermaLife
189 DermaLife
209 DermaLife
aCulture ID refers to the unique number assigned to a patient during the
process of sample anonymization; HuMEC = HuMEC Ready Medium (GIBCO/
Invitrogen, Breda, The Netherlands); DermaLife = DermaLife K Serum-Free
Keratinocyte Culture Medium (Lifeline Cell Technology, Walkersville, MD, USA).
Table 3 Primers used to genotype four SNPs in FGFR2
a
SNP Primer Primer sequence (5’ to 3’) Product
length
Annealing
temperature
Further analysis
rs10736303 F AGGGACAAATACTCCGCACA 405 bp 50°C Sanger sequencing
R AGCCATCCAGCATGTTTCTC
rs2981578 F TGACTCTTCAAAGTTTGTTTGTTTT 295 bp 50°C Restriction enzyme AciI (New England Biolabs, Ipswich,
MA, USA)
R GAGGAAAGGTTCCCCACACT
rs2981582 F AGCTCAGCTTACCCCAGACA 215 bp 58°C Restriction enzyme AciI (New England Biolabs, Ipswich,
MA, USA)
R CGTGAGCCAAGCCTCTACTT
rs7895676 F CAGGTGCGGTGGCTCATGTC 345 bp 67°C Sanger sequencing
R GACTTCAATGGCGGGACTCC
aFGFR2: fibroblast growth factor receptor 2 gene; F: forward primer; R: reverse primer; bp: base pair. For each SNP, the forward and reverse primer sequences, the
length of the resulting PCR product and the annealing temperature used during PCR are shown. Also shown is the technique that was used on the resulting PCR
fragment to genotype the SNPs.
Huijts et al. Breast Cancer Research 2011, 13:R72
http://breast-cancer-research.com/content/13/4/R72
Page 3 of 12low (n =4 )FGFR2 mRNA levels. Total protein isolation
and Western blot analysis are described in detail in the
supplementary methods section (Additional file 2). Each
sample was measured twice on separate gels. The pri-
mary and secondary antibodies used are given in Table
5. The Odyssey Infrared Imaging System and Odyssey
3.0 software (LI-COR Biotechnology, Cambridge, UK)
were used to visualize and identify the bands.
Analyzing the phosphorylation of downstream FGFR2
targets
Five skin fibroblast cultures with high FGFR2 mRNA
expression and five skin fibroblast cultures with low
FGFR2 mRNA expression were randomly selected. In
each experiment, one culture with high mRNA expres-
sion and one culture with low mRNA expression were
compared. In each well of a six-well plate, 5 × 10
5 fibro-
blasts from the full cell culture flasks were seeded and
10% FCS medium was added. The cells were allowed to
attach to the well bottom for 24 hours and were then
starved in 0.5% FCS medium for 12 hours. Cells were
subsequently exposed to 0 or 20 ng of FGF2 (basic
fibroblast growth factor, 9952; Cell Signaling Technol-
ogy, Danvers, MA, USA) in 0.5 mL of 0.5% FCS medium
for 10 minutes. This length of time was chosen because
in an initial experiment phosphorylation levels peaked at
about 10 minutes (Figure S2 in Additional file 3).
Total protein was then isolated, and Western blot ana-
lysis was performed to assess the phosphorylation of
downstream targets of FGFR2 as described in more
detail in the supplementary methods section (Additional
file 2). The primary and secondary antibodies that were
used are given in Table 5. Phosphorylation levels after
10 minutes of exposure were normalized to phosphory-
lation levels before exposure.
Determining the stroma percentage within the primary
tumor
Routine H & E-stained histological tumor sections were
obtained from the Department of Pathology for 50 of
the 68 patients from whom skin fibroblast cultures were
available. The stroma percentage within the primary
tumor was estimated by two researchers as previously
described [18].
Immunohistochemistry
For the immunohistochemical analyses, patients were
selected for being either homozygous for the risk allele
and having high FGFR2 mRNA expression (n = 11) or
f o rb e i n gh o m o z y g o u sf o rt h em a j o ra l l e l ea n dh a v i n g
Table 4 Primers used during real-time PCR analyses
a
Gene and
(GeneID)
b
Sequence
ID
Primer Primer sequence (5’ to 3’) Product
length
Distance from poly(A)
tail
c
Exon-exon
boundary
FGF2 NM_002006.4 F ACCTGCAGACTGCTTTTTGCCCA 91 bp 1,731 bp No
(2247) R GGTGCCACGTGAGAGCAGAGC
FGF7 NM_002009.3 F CTCAACGGCAAGTTTCCCTCCCTTTTC 80 bp 1,701 bp No
(2252) R GCCTTCCAGGATTTGCTGGCCC
FGF10 NM_004465.1 F TCTTCTTCCTCCTCCTTCTCCTCTCC 148 bp 325 bp No
(2255) R TCCCGCTGACCTTCCCGTTCTTCTC
FGFR2
d NM_000141.4 F GTCAGTGAGAACAGTAACAACAAG 192 bp 3,368 bp Yes
(2263) R GTAGCCTCCAATGCGATGC
GADPH NM_002046.3 F TTCCAGGAGCGAGATCCCT 175 bp 805 bp Yes
(2597) R CACCCATGACGAACATGGG
HMBS NM_000190.3 F CTGGTAACGGCAATGCGGCT 338 bp 1010 bp Yes
(3145) R GCAGATGGCTCCGATGGTGA
HNRPM NM_005968.3 F GAGGCCATGCTCCTGGG 85 bp 440 bp Yes
(4670) R TTTAGCATCTTCCATGTGAAATCG
HPRT1 NM_000194.2 F TGACACTGGCAAAACAATGCA 94 bp 742 bp Yes
(3251) R GGTCCTTTTCACCAGCAAGCT
SRPR NM_003139.2 F CATTGCTTTTGCACGTAACCAA 70 bp 1,308 bp Yes
(6734) R ATTGTCTTGCATGCGGCC
TBP NM_003194.3 F CACGAACCACGGCACTGATT 89 bp 905 bp Yes
(6908) R TTTTCTTGCTGCCAGTCTGGAC
aFGF: fibroblast growth factor gene; FGFR: fibroblast growth factor receptor gene; GAPDH: glyceraldehyde 3-phosphate dehydrogenase gene; HMBS:
hydroxymethylbilane synthase gene; HNRPM: heterogeneous nuclear ribonucleoprotein M gene; HPRT1: hypoxanthine phosphoribosyltransferase 1 gene; SRPR:
signal recognition particle receptor gene; TBP: TATA box binding protein gene; F: forward primer; R: reverse primer; bp: base pair. For each gene, the forward and
reverse primer sequences, the length of the resulting PCR product (using cDNA as template) and the distance from the poly(A) tail are shown, as is the
information about whether the PCR product includes an exon-exon boundary.
bGeneID from EntrezGene accessed 2 June 2010.
cDistance from 3’ end of the PCR
product to 5’ beginning of the poly(A) tail.
dPrimer set for FGFR2 is in a region of FGFR2 that is present in both FGFR2 IIIb and FGFR2 IIIc.
Huijts et al. Breast Cancer Research 2011, 13:R72
http://breast-cancer-research.com/content/13/4/R72
Page 4 of 12low FGFR2 mRNA expression (n = 14). Tissue sections
were stained using antibodies to detect the presence of
microvessels (CD31) and T lymphocytes (CD3). Micro-
vascular density was measured by two independent
observers who counted all CD31-stained blood vessels
in 10 high-power fields (HPFs) randomly selected within
the tumor region. The average number of blood vessels
per HPF was then calculated and used in subsequent
analysis. For CD3, slides were scanned using the Pan-
noramic MIDI digital scanner (3DHISTECH Ltd., Buda-
pest, Hungary) and then viewed at ×10 magnification
using the MIRAX Viewer 1.11 (3DHISTECH Ltd.). For
each tumor, four to six representative areas of 1,800 μm
× 1,200 μm were selected, and the tumor and surround-
ing stroma were separately analyzed using ImageJ soft-
ware and the color deconvolution plug-in [19]. The area
covered by the antibody was measured and normalized
by dividing it by the area covered by nuclei.
Statistical analysis
The distribution of the SNP genotypes was studied
using an Excel-based Hardy-Weinberg equilibrium
(HWE) calculator [20]. For all other statistical analyses,
we used PASW Statistics version 17.0 software (SPSS
Inc., Nieuwegein, The Netherlands).
Results
A total of 68 skin fibroblast cultures, 44 breast fibroblast
cultures, 11 tumor-derived fibroblast cultures and 25
skin epithelial cell cultures were established from 98
patients who had undergone breast cancer-related sur-
gery at LUMC. We genotyped four SNPs in intron 2 of
FGFR2 (Table 6). All SNPs were in HWE. SNP
rs2981578 was chosen to represent all four SNPs
because of its reported effect on the binding of tran-
scription factor Runx2 and because it showed strong LD
with the other three SNPs including rs2981582.
FGFR2 mRNA expression in fibroblasts and epithelial cells
A significant correlation between the rs2981578 geno-
type and FGFR2 mRNA expression level as measured by
qRT-PCR was present in the 68 skin fibroblast cultures
(Figure 1A) (P = 0.02; one-way analysis of variance
(ANOVA)). Although expression levels varied widely
within each genotype group, a dosage-dependent effect
was seen, with the highest average expression found
among homozygotes for the minor allele (the risk allele),
followed by heterozygotes, and the lowest average
expression found among homozygotes for the major
allele. In contrast, among 25 skin epithelial cell cultures,
there were no statistically significant differences in
FGFR2 mRNA expression levels between the three gen-
otype groups, although the average levels of FGFR2
mRNA were slightly lower in carriers of one or two
copies of the risk allele (Figure 1B) (P =0 . 7 3 2 ;o n e - w a y
ANOVA).
Table 5 Antibodies used during Western blot analyses
a
Antigen targeted Antibody (catalog number, manufacturer) Clonality Dilution Origin
Primary antibodies
FGFR2 Bek C-17 (sc-122, SZ) Polyclonal 1 in 500 Rabbit
a-tubulin Anti-a-tubulin (T6199, SA) Monoclonal 1 in 8,000 Mouse
ERK1/2 p44/42 MAPK antibody (9102, CS) Polyclonal 1 in 100 Rabbit
Phosphorylated ERK1/2 Phospho-p44/42 MAPK antibody (4377, CS) Monoclonal 1 in 200 Rabbit
FRS2a FRS2 H-91 (sc-8318, SZ) Polyclonal 1 in 50 Rabbit
Phosphorylated FRS2a Phospho-FRS2-a antibody (3864, CS) Polyclonal 1 in 50 Rabbit
Secondary antibodies
Mouse IgG IRDye 680 anti-mouse IgG (926-32220, LC) Polyclonal 1 in 7,500 Goat
Rabbit IgG IRDye 800CW anti-rabbit IgG (926-32211, LC) Polyclonal 1 in 5,000 Goat
aFGFR2: fibroblast growth factor receptor 2 gene; ERK1/2: extracellular signal-regulated kinases 1 and 2; FRS2a: fibroblast growth factor receptor substrate 2a;
IgG: immunoglobulin G; MAPK: mitogen-activated protein kinase. Manufacturer names are abbreviated as follows: SZ: Santa Cruz Biotechnology, Santa Cruz, CA,
USA; SA: Sigma-Aldrich, Zwijndrecht, The Netherlands; CS: Cell Signaling Technology, Danvers, MA, USA; LC, LI-COR Biosciences, Cambridge, UK. For each
antibody, the target, manufacturer, clonality, dilution used during Western blot analysis and origin are given.
Table 6 Genotype distribution of four SNPs in FGFR2
a
rs2981582 rs2981578 rs10736303 rs7895676 Number of
patients
CT AG AG CT 29
TT GG GG CC 22
CC AA AA TT 21
CT GG GG CC 7
CC AG AG CT 5
TT AA AA TT 1
Total 85
b
aFGFR2: fibroblast growth factor receptor 2 gene. The number of patients who
carry each combination of the four genotypes is shown in the right-hand
column. Although we have no haplotype information, the genotype
distribution shows the strong linkage disequilibrium present within this
region. The alleles associated with increased breast cancer risk are rs2981582:
T; rs2981578: G; rs10736303: G; and rs7895676: C.
bFor the remaining13
patients, only rs2981578 was genotyped; of these patients, 5 carried AA, 5
carried AG and 3 carried GG.
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different tissues
To address whether FGFR2 expression levels in skin
fibroblasts correlated to those in breast fibroblasts, we
cultured fibroblasts from the skin tissue as well as the
normal breast tissue from 22 breast cancer patients.
There was a significant correlation between the FGFR2
mRNA levels in the skin fibroblasts and the breast
fibroblasts (Figure 2A) (Pearson’s correlation coefficient
= 0.64, P = 0.001). Expression levels were on average 2.8
times higher in the breast fib r o b l a s t st h a ni nt h es k i n
fibroblasts (P = 0.001; paired t-test).
For 11 of these 22 patients, we also successfully grew
fibroblasts from the tumor tissue. FGFR2 mRNA expres-
sion in tumor-derived fibroblasts was on average eight
times higher than in breast fibroblasts and sixteen times
higher than in skin fibroblasts (Figure 2B) (P =3×1 0
-4
and P =2×1 0
-4, respectively; paired t-tests).
Figure 1 The relationship between FGFR2 mRNA expression
and the rs2981578 genotype in skin fibroblast and skin
epithelial cell cultures. (A) A significant correlation between the
rs2981578 genotype and FGFR2 mRNA expression level as measured
by quantitative real-time PCR was present in the 68 skin fibroblast
cultures (P = 0.02; one-way ANOVA). The expression levels were
log2-transformed and normalized to HNRPM and TBP expression. (B)
FGFR2 mRNA expression and rs2981578 genotypes in 25 skin
epithelial cell cultures (P = 0.73; one-way ANOVA). The expression
levels were log2-transformed and normalized to HNRPM, SRPR and
TBP expression. Each dot represents the expression level in one
patient.
Figure 2 FGFR2 mRNA expression levels in fibroblasts cultured
from different locations. (A) We found a significant correlation
between FGFR2 mRNA expression in skin fibroblasts and normal
breast fibroblasts from the same patient (n = 22). The FGFR2
expression levels were log2-transformed and normalized to HNRPM
and TBP expression. (B) FGFR2 mRNA expression in tumor-derived
fibroblasts is significantly higher than in fibroblasts cultured from
normal breast tissue. The FGFR2 expression levels were log2-
transformed and normalized to HNRPM and TBP expression. Each
dot represents FGFR2 expression in one patient. The lines connect
the fibroblast cultures from one patient. The horizontal bars shows
the mean expression for all fibroblast cultures from that origin (skin
-3.8 (±1.9 SD), normal breast -2.9 (±1.4 SD), tumor tissue 0.2 (±1.5
SD)). *P < 0.001.
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and epithelial cells
Since an isoform switch from FGFR2 IIIb to FGFR2 IIIc
has been reported in a few breast cancer cell lines, and
since this switch may contribute to tumor development,
we explored whether rs2981578 genotype influences the
alternative splicing of isoforms of FGFR2. The expected
FGFR2-IIIb was detected in 14 epithelial cell cultures,
and the expected FGFR2-IIIc was detected in 48 of 52
fibroblast cultures. In the remaining four fibroblast sam-
ples, FGFR2-IIIb was present at a level approximately
10% of that of FGFR2-IIIc, but the presence or absence
of FGFR2-IIIb was not associated with rs2981578 geno-
type (P = 0.32; Pearson’s c
2 test).
Correlation between FGFR2 and FGF10 mRNA expression
To explore a possible paracrine relationship between
fibroblasts and epithelial cells, the mRNA expression
levels of FGF2, FGF7 and FGF10 were measured in the
68 skin fibroblast cultures and compared to their FGFR2
mRNA expression. FGF2 mRNA expression was not
correlated with FGFR2 expression (Figure 3C) (Pearson’s
correlation coefficient = 0.22, P = 0.07). The correlation
between FGFR2 and FGF7 mRNA levels in skin fibro-
blasts did not remain significant after correction for
multiple testing (Figure 3B) (Pearson’s correlation coeffi-
cient = 0.28, P = 0.02).
FGFR2 and FGF10 expression levels were loosely but
significantly correlated in the skin fibroblast cultures
(Figure 3A) (Pearson’s correlation coefficient = 0.60, P =
8×1 0
-8). There was also a suggestive correlation
between FGF10 expression and rs2981578 genotype in
these cultures (P = 0.06; one-way ANOVA) (Figure S3
in Additional file 4). In 44 fibroblast cultures from nor-
mal breast tissue, there was a suggestive correlation
between FGFR2 and FGF10 mRNA levels (Spearman’s r
= 0.25, P = 0.11) (Figure S4 in Additional file 5).
FGFR2 protein expression
In seven fibroblast cultures, FGFR2 protein levels were
quantified by Western blot analysis and compared with
the FGFR2 mRNA levels. The FGFR2 antibody that was
used detected a full-length FGFR2 recombinant protein,
but absolute protein expression levels in fibroblasts were
very low, giving poor signal-to-noise ratios. Possibly as a
result of this, we were unable to demonstrate a correla-
tion between FGFR2 mRNA and protein levels (Spear-
man’s r = -0.14, P = 0.76) (Figure S5 in Additional file 6).
Phosphorylation of downstream FGFR2 targets
To investigate whether the differences in FGFR2 mRNA
expression levels correspond with different levels of
FGFR2 pathway activity, we compared the phosphoryla-
tion of downstream targets FGF receptor substrate 2a
Figure 3 Correlation of expression levels of FGFR2 and FGF10
mRNA in 68 skin fibroblast cultures. No correlation was found for
FGFR2 and FGF2 mRNA or FGFR2 and FGF7 mRNA levels. The data
were normalized to HNRPM and TBP and log2-transformed. Each dot
represents the expression levels from one patient. (A) FGFR2 and
FGF10 (P =8×1 0
-8; Pearson’s correlation). (B) FGFR2 and FGF7 (P =
0.02; Pearson’s correlation). (C) FGFR2 and FGF2 (P = 0.07; Pearson’s
correlation).
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2 (ERK1/2) after 10 minutes of exposure to ligand FGF2
in skin fibroblast cultures with high and low FGFR2
mRNA levels. Duplicate measurements correlated well
in all experiments (Pearson’s correlation coefficient =
0.92, P =8×1 0
-65).
Phosphorylation of FRS2a was measured in four fibro-
blast cultures, two with high and two with low FGFR2
expression. The sample with higher FGFR2 expression
showed a larger increase in phosphorylation of FRS2a
after FGF2 was added compared to the sample with
lower FGFR2 expression (Figure 4) (P = 0.18; Wilcoxon
signed-rank test).
Phosphorylation of ERK1/2 increased in all skin fibro-
blast cultures after exposure to FGF2, and this effect
was again more pronounced in the sample with higher
FGFR2 expression in all five experiments (Figure 4) (P =
0.04; Wilcoxon signed-rank test).
FGFR2 mRNA level and histological breast tumor
characteristics
We explored tumor parameters in patients with differ-
ent FGFR2 mRNA levels in their fibroblasts. Since the
percentage of stroma in the primary tumor may vary
considerably [18] and FGFR2 signaling in the stroma
could influence cell proliferation, we explored whether
patients with higher FGFR2 mRNA expression in fibro-
blasts had a higher stroma percentage. In the 50 patients
analyzed, no correlation was present between FGFR2
mRNA levels in their fibroblasts and the percentage of
stroma within the tumor (Spearman’s r = 0.17, P =
0.23). Unfortunately, not enough tumor tissue was avail-
able from patients from whom we had obtained skin
epithelial cells.
Because FGF signaling in cancer has been associated
with induction of angiogenesis and lymphocytic infiltra-
tion [21], the number of microvessels was determined
and T-cell infiltrate was quantified in breast tumors
from patients whose fibroblasts had relatively high (n =
11) or relatively low (n = 14) FGFR2 expression. Inter-
observer agreement regarding the number of blood ves-
sels per HPF was high (Pearson’s correlation coefficient
=0 . 8 9 ,P =1×1 0
-5), but no correlation with FGFR2
mRNA levels was present (Pearson’s correlation coeffi-
cient = 0.04, P = 0.86). No correlations between the
amount of T-cell infiltrate and FGFR2 mRNA levels in
the fibroblasts were detected either (T cells in stroma:
Pearson’s correlation coefficient = 0.04, P = 0.86; T cells
in tumor: Pearson’s correlation coefficient = 0.15, P =
0.52).
Finally, since the SNPs in intron 2 of FGFR2 are
mainly associated with estrogen receptor-positive (ER-
positive) breast tumors [1,22], we studied a possible cor-
relation between FGFR2 mRNA levels and ER status of
the tumor in 50 patients, but could detect none (P =
0.60; logistic regression).
Discussion
Aberrant FGF signaling has been implicated in the
pathogenesis of multiple types of cancer, including
breast cancer [11,23]. Germline genetic variation in an
LD region within intron 2 of FGFR2 has been associated
with a modestly increased breast cancer risk. Fine-scale
genetic mapping and functional analyses identified up to
eight SNPs, including SNP rs2981578, as likely causal
variants [1,5,7]. It was demonstrated that these SNPs
influence mRNA expression levels of the FGFR2 gene.
Despite this progress, substantial uncertainty remains
regarding how subtle modulation of FGFR2 expression
levels may modify breast cancer risk. In addition, oppo-
site effects of intron 2 SNP genotypes on FGFR2 mRNA
expression have been reported in tumor tissue and nor-
mal breast tissue [7,8].
We found, on average, higher FGFR2 mRNA levels in
skin fibroblast cultures of heterozygotes and homozy-
gotes for the risk allele of SNP rs2981578 relative to
homozygotes for the major allele. This is in agreement
with measurements of FGFR2 mRNA expression in total
RNA from breast tumor tissue [7]. However, no effect
of genotype was observed in our skin epithelial cell cul-
tures. Also, epithelial breast tumor cells express lower
levels of FGFR2 than surrounding normal breast
Figure 4 Response of skin fibroblast cultures with high and
low FGFR2 mRNA levels to stimulation with ligand FGF2.
Phosphorylation of downstream targets FRS2a and ERK1/2 were
measured before and after 10 minutes of stimulation with FGF2.
The average difference of the increase in phosphorylation is shown,
which was calculated by dividing the increase in samples with high
FGFR2 mRNA levels by the increase in samples with low FGFR2
mRNA levels. The 95% confidence intervals are also shown.
Phosphorylation of FRS2a was measured in four fibroblast cultures:
two with high and two with low FGFR2 mRNA levels.
Phosphorylation of ERK1/2 was measured in 10 fibroblast cultures,
five with high and five with low FGFR2 mRNA levels.
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tumor cells may induce expression changes in neighbor-
ing normal cells, leading to gene expression differences
between tumor-derived stromal fibroblasts and normal
breast stroma [24]. In the 11 patients from whom we
obtained fibroblasts from skin, normal breast tissue and
breast tumor tissue, FGFR2 expression levels in the
tumor-derived fibroblasts were consistently higher than
in the fibroblasts from normal breast tissue. A similar
finding was made recently in cell cultures from patients
with esophageal cancer [25]. Unfortunately, our sample
set was too small to conclusively establish whether
expression levels of FGFR2 mRNA in tumor-derived
fibroblasts are similarly associated with SNP genotypes
in intron 2 as they are in skin-derived fibroblasts. Taken
together, however, these data suggest that the associa-
tion between genotype and FGFR2 expression observed
by Meyer et al. [7] in total breast tumor homogenates
was derived from cancer-associated fibroblasts rather
than from the tumor (or epithelial) component. Because
the transcription factors Oct-1/Runx2 and C/EBPb dis-
play differential binding to these SNP alleles in epithelial
breast tumor cells, it will be interesting to study this in
other cell types constituting breast tumor stroma.
Our results in fibroblast and epithelial cell cultures are
at odds with those obtained by Sun et al.[ 8 ] ,w h or e p o r t e d
lower FGFR2 mRNA expression in normal breast tissue
from homozygotes for the risk allele. However, the differ-
ences reported by Sun et al. were small and the correlation
was weak. In our epithelial cell cultures, there was a trend
toward lower FGFR2 mRNA expression in carriers of one
or two copies of the risk allele, but the differences were
very small. The insufficient statistical power of our studies
or the differences in experimental design (whole tissue
analysis versus analysis of cultured epithelial cells) may
underlie these different outcomes.
The variation in FGFR2 mRNA expression between
individuals with the same intron 2 genotype is wide in
both fibroblasts and epithelial cells. Apparently, the cau-
sal variants in intron 2 of FGFR2 only partly determine
the FGFR2 mRNA expression level. We have shown that
in skin fibroblasts, higher FGFR2 mRNA levels corre-
spond to higher activity of the FGFR2 pathway upon sti-
mulation by ligand FGF2, indicating that the allelic
status of the intron 2 SNPs is functional at the FGF sig-
naling level. Cells with higher FGFR2 expression prob-
ably respond differently to the same fibroblast growth
factor concentration in their microenvironment [26].
Thus, the overall activity of the FGFR2 pathway might
be a more accurate predictor of breast cancer risk than
rs2981578 or rs2981582 genotype status, although it is
presently unclear through which cell type and in which
developmental phase of the mammary gland this activity
contributes most to this risk.
Fibroblasts have a well-recognized role in the carcino-
genic process as remodelers of the extracellular matrix
in tumor stroma and as a source of paracrine growth
factors that influence the growth of carcinoma cells
[27,28]. Unequivocal evidence that paracrine FGF
released from breast tumor stroma functions to promote
tumorigenesis is lacking, but, intriguingly, we found a
strong correlation between FGFR2 and FGF10 mRNA
expression levels in the cultured skin fibroblasts. We
have not investigated the mechanism underlying this
correlation, nor have we been able to establish that it
also holds true for tumor-derived fibroblasts. Since
FGF10 is known to be secreted by fibroblasts and to
bind specifically to the FGFR2-IIIb isoform expressed on
epithelial cells, however, our findings would fit a model
of paracrine tumor-stroma interaction. The FGFR2-IIIb-
FGF10 interaction plays a key role in the normal embry-
ological and postnatal development of the mammary
glands in mice [29,30]. Mice deficient in Fgf10 or Fgfr2b
fail to develop normal mammary glands. Apparently,
Fgfr2b signaling is crucial for the survival and prolifera-
tion of the mammary luminal epithelial cells but does
not affect the regenerative potential of the mammary
epithelial progenitor cells. Fgf10 overexpression in the
stromal compartment of the murine prostate results in
epithelial cell hyperproliferation [31]. Also, in humans,
FGF10 is thought to stimulate epithelial cell prolifera-
tion [32].
Thus, it is conceivable that, in the human breast,
slightly increased levels of FGFR2 and FGF10 result in a
slightly increased ductal branching. If this primarily
involved the luminal epithelial component of the breast
tissue as it does in mice, this would explain why the
increased breast cancer risk conferred by FGFR2 intron
2 SNPs is mostly restricted to ER-positive tumors
[22,33]. High FGF2 and/or FGFR2 protein levels have
been correlated with high ER levels in breast cancer
[34,35]. Our cohort was probably underpowered to
demonstrate a correlation between ER status of the
tumor and FGFR2 mRNA expression levels in skin
fibroblasts. FGF7, also secreted by breast fibroblasts, has
similarly been suggested to act as a paracrine growth
factor in human breast cancer [36], but our data do not
demonstrate a significant link between FGF7 and FGFR2
expression.
In pancreatic cancer, FGF10 is found in stromal cells,
close to the tumor cells, and is thought to interact with
FGFR2-IIIb on the tumor cells, thereby inducing cell
migration and invasion [37]. Since the downstream
effects of activation of FGFR2 by different FGFs in dif-
ferent cell types are very diverse and could include
apoptosis, cell proliferation and angiogenesis [11], it is
difficult to predict which of these effects could mechan-
istically explain the increased breast cancer risk
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some of the end points of these processes in breast
tumors from patients with different FGFR2 mRNA levels
in their fibroblasts. Tsunoda et al.[ 3 8 ]r e p o r t e d
increased T-lymphocyte and macrophage infiltration
into a newly inoculated tumor when they injected FGF2
into this tumor. In mice, overexpression of Fgf10 leads
to highly vascularized tumors in immunocompetent
mice [39]. However, we found no correlation between
FGFR2 mRNA levels and, respectively, stroma percen-
tage of the tumor, microvessel density and T-cell infil-
trate. Our sample size may have been too small to
detect any existing differences, in particular because
these differences can be expected to be small, given the
mildly increased breast cancer risks conferred by FGFR2
SNPs.
A limitation of our study is that our observations were
based on cultured cells from surgically removed tissues.
Culture conditions between fibroblasts and epithelial
cells were necessarily different and may have influenced
some of our findings, but this enabled us to study RNA
expression levels by cell type instead of by heteroge-
neous tissue. It has long been known that the phenotype
of fibroblasts can differ depending on anatomical site
[40-43]. Indeed, we did observe absolute differences in
FGFR2 mRNA expression levels between fibroblasts
from skin tissue and those from normal breast tissue,
but we demonstrated that these correlate very well (Fig-
ure 2).
Conclusions
In conclusion, it is likely that the causative variants
tagged by rs2981578 in intron 2 of the FGFR2 gene
cause a higher breast cancer risk by influencing FGFR2
expression levels. Here we have shown that the effect of
intron 2 SNPs on FGFR2 expression is cell type-specific.
Different effects were observed in skin fibroblasts and
epithelial cells. Tissue specificity for expression quantita-
tive trait loci is common [44] and clearly also applies to
FGFR2.
In addition, we observed differences in the levels of
FGFR2 mRNA expression between fibroblasts derived
from normal breast tissue or from tumor tissue, which
strongly supports a holistic model to explain FGFR2-
related breast cancer risk [45] rather than one assuming
cell autonomous effects of FGFR2 expression modula-
tion. Our finding that individuals in whom intrinsically
higher levels of FGFR2 are expressed in their skin fibro-
blasts also have higher levels of FGF10 suggests that the
increased breast cancer risk might be due to a stronger
paracrine effect between stromal and tumor cells invol-
ving FGF10 signaling. The fact that the association
between FGFR2 and FGF10 expression was not observed
by Meyer et al. [7] in 45 normal breast tissue samples
underscores the importance of analyzing the various
constituting cell types separately in sufficiently large
cohorts. Since we limited our search for such associa-
tions to FGFs secreted by fibroblasts, and given that the
FGFR2 and FGF10 genes are located on different chro-
mosomes, it will be important to extend these analyses
to genome-wide expression differences between different
cell types in various FGFR2 genotype backgrounds.
Additional material
Additional file 1: Figure S1. (A) Typical fibroblast and (B) typical
epithelial cell cultures (original magnification, ×10).
Additional file 2: Supplementary methods. This file contains
supplementary methods regarding the quantitative real-time PCR and
Western blot analyses.
Additional file 3: Figure S2. Phosphorylation levels of downstream
targets of FGFR2 after different periods of stimulation with FGF2 in one
fibroblast sample (sample from experiment 1 with high FGFR2 mRNA
levels). (A) Using one of the blots as an example, we show
phosphorylated ERK1/2 examined after 0, 1, 5, 10 and 20 minutes. H:
lanes with total protein from a fibroblast sample with high FGFR2 mRNA
level; L: lanes from a fibroblast sample with low FGFR2 mRNA level; M:
lane with the length marker; T: tubulin, E1/2 ERK1/2. (B) Phosphorylation
levels of FRS2a, ERK1 and ERK2 are shown as fold increases compared to
the phosphorylation levels at 0 minutes of stimulation.
Additional file 4: Figure S3. The relationship between FGF10 mRNA
expression and the rs2981578 genotype in 68 skin fibroblast cultures (P =
0.06; one-way ANOVA). The expression levels were log2-transformed and
normalized to HNRPM and TBP expression.
Additional file 5: Figure S4. Correlation of expression levels of FGFR2
and FGF10 mRNA in 44 breast fibroblast cultures. FGFR2 and FGF10
expression levels were normalized to HNRPM and TBP and log2-
transformed. Each dot represents the expression levels of one patient
(Spearman’s r = 0.25, P = 0.11).
Additional file 6: Figure S5. Western blot analysis measuring FGFR2
protein levels in fibroblasts. (A) Western blot showing results for seven
different fibroblast cultures. H: lanes with total protein from fibroblasts
with high FGFR2 mRNA levels; L: lanes with total protein from fibroblasts
with low FGFR2 mRNA levels; empty: empty lane; M: lane with length
marker; recomb: lane with pure recombinant FGFR2. (B) FGFR2 mRNA
levels and FGFR2 protein levels in the seven fibroblast samples. The
FGFR2 mRNA results were normalized to HNRPM and TBP and log2-
transformed. The FGFR2 protein results were normalized to a-tubulin.
Each dot represents the results for one fibroblast sample.
Abbreviations
bp: base pairs; C/EBPβ: CCAAT/enhancer binding protein β; CI: confidence
interval; ER: estrogen receptor; ERK1/2: extracellular signal-regulated kinases 1
and 2; FCS: fetal calf serum; FGFR2: fibroblast growth factor receptor 2 gene;
FGF: fibroblast growth factor; FRS2α: fibroblast growth factor receptor
substrate 2α; H & E: hematoxylin and eosin; HNRPM: heterogeneous nuclear
ribonucleoprotein M; HPF: high-power field; HWE: Hardy-Weinberg
equilibrium; LD: linkage disequilibrium; MAPK: mitogen-activated protein
kinase; Oct-1: octamer-binding transcription factor 1; OR: odds ratio; PCR:
polymerase chain reaction; qPCR: quantitative real-time PCR; Runx2: runt-
related transcription factor 2; SNP: single-nucleotide polymorphism; SRPR:
signal recognition particle receptor; TBP: TATA box binding protein.
Acknowledgements
The authors thank JJ Baelde, EJ Dreef, FA Prins and KR Straasheijm for their
technical assistance and EMM Krol Warmerdam for patient recruitment. This
work was supported by the Dutch Cancer Society (grant 2006-3477). The
Huijts et al. Breast Cancer Research 2011, 13:R72
http://breast-cancer-research.com/content/13/4/R72
Page 10 of 12funders had no role in the study design, data collection and analysis,
decision to publish or preparation of the manuscript.
Author details
1Department of Clinical Genetics, Leiden University Medical Center, PO Box
9600, 2300 RC Leiden, The Netherlands.
2Department of Human Genetics,
Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The
Netherlands.
3Department of Surgery, Leiden University Medical Center, PO
Box 9600, 2300 RC Leiden, The Netherlands.
4Department of Medical
Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600,
2300 RC Leiden, The Netherlands.
5Department of Pathology, Leiden
University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Authors’ contributions
The experiments were performed by PH, MD, MG and AM. The patient
material was provided by RT and VS. The cells were cultured by FB and MV.
The stroma percentage of 50 tumors was analyzed by EK and WM. The
experiments were designed, analyzed and interpreted by PH, CA and PD. EZ
helped with the statistical analyses and the interpretation of the data. The
manuscript was drafted by PH and critically revised by MV, CA and PD. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 December 2010 Revised: 13 May 2011
Accepted: 18 July 2011 Published: 18 July 2011
References
1. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D,
Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N,
Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB,
Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P,
Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D,
Evans DG, et al: Genome-wide association study identifies novel breast
cancer susceptibility loci. Nature 2007, 447:1087-1093.
2. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE,
Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N,
Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA,
Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS,
Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ: A genome-wide
association study identifies alleles in FGFR2 associated with risk of
sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874.
3. Kawase T, Matsuo K, Suzuki T, Hiraki A, Watanabe M, Iwata H, Tanaka H,
Tajima K: FGFR2 intronic polymorphisms interact with reproductive risk
factors of breast cancer: results of a case control study in Japan. Int J
Cancer 2009, 125:1946-1952.
4. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J, Wang H,
Shen H: Genetic variants in fibroblast growth factor receptor 2 (FGFR2)
contribute to susceptibility of breast cancer in Chinese women.
Carcinogenesis 2008, 29:2341-2346.
5. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, Doody DR,
MacArthur S, Tyrer J, Pharoah PD, Luben R, Bernstein L, Kolonel LN,
Henderson BE, Le Marchand L, Ursin G, Press MF, Brennan P, Sangrajrang S,
Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Kang D, Yoo KY,
Noh DY, Ahn SH, Ponder BA, Haiman CA, SEARCH Collaborators: FGFR2
variants and breast cancer risk: fine-scale mapping using African
American studies and analysis of chromatin conformation. Hum Mol
Genet 2009, 18:1692-1703.
6. Zheng W, Cai Q, Signorello LB, Long J, Hargreaves MK, Deming SL, Li G,
Li C, Cui Y, Blot WJ: Evaluation of 11 breast cancer susceptibility loci in
African-American women. Cancer Epidemiol Biomarkers Prev 2009,
18:2761-2764.
7. Meyer KB, Maia AT, O’Reilly M, Teschendorff AE, Chin SF, Caldas C,
Ponder BA: Allele-specific up-regulation of FGFR2 increases susceptibility
to breast cancer. PLoS Biol 2008, 6:e108.
8. Sun C, Olopade OI, Di RA: rs2981582 is associated with FGFR2 expression
in normal breast. Cancer Genet Cytogenet 2010, 197:193-194.
9. Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast
growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
10. Knights V, Cook SJ: De-regulated FGF receptors as therapeutic targets in
cancer. Pharmacol Ther 2010, 125:105-117.
11. Turner N, Grose R: Fibroblast growth factor signalling: from development
to cancer. Nat Rev Cancer 2010, 10:116-129.
12. Zhu X, Asa SL, Ezzat S: Genetic and epigenetic mechanisms down-
regulate FGF receptor 2 to induce melanoma-associated antigen A in
breast cancer. Am J Pathol 2010, 176:2333-2343.
13. Penault-Llorca F, Bertucci F, Adélaïde J, Parc P, Coulier F, Jacquemier J,
Birnbaum D, deLapeyrière O: Expression of FGF and FGF receptor genes
in human breast cancer. Int J Cancer 1995, 61:170-176.
14. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G,
Teague J, Smith R, Stevens C, O’Meara S, Parker A, Tarpey P, Avis T,
Barthorpe A, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E,
Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K,
Hinton J, Jones D, et al: A screen of the complete protein kinase gene
family identifies diverse patterns of somatic mutations in human breast
cancer. Nat Genet 2005, 37:590-592.
15. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M: Alternative splicing of
fibroblast growth factor receptors in human prostate cancer. Prostate
2001, 46:163-172.
16. Luqmani YA, Bansal GS, Mortimer C, Buluwela L, Coombes RC: Expression
of FGFR2 BEK and K-SAM mRNA variants in normal and malignant
human breast. Eur J Cancer 1996, 32A:518-524.
17. Zhu X, Asa SL, Ezzat S: Histone-acetylated control of fibroblast growth
factor receptor 2 intron 2 polymorphisms and isoform splicing in breast
cancer. Mol Endocrinol 2009, 23:1397-1405.
18. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ,
Kuppen PJ, Tollenaar RA, Mesker WE: Tumor-stroma ratio in the primary
tumor is a prognostic factor in early breast cancer patients, especially in
triple-negative carcinoma patients. Breast Cancer Res Treat 2011,
125:687-696.
19. Ruifrok AC, Johnston DA: Quantification of histochemical staining by
color deconvolution. Anal Quant Cytol Histol 2001, 23:291-299.
20. Court lab HW calculator. [http://www.tufts.edu/~mcourt01/Documents/
Court%20lab%20-%20HW%20calculator.xls].
21. Acevedo VD, Ittmann M, Spencer DM: Paths of FGFR-driven
tumorigenesis. Cell Cycle 2009, 8:580-588.
22. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA,
Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G,
González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C,
Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P,
Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K,
et al: Heterogeneity of breast cancer associations with five susceptibility
loci by clinical and pathological characteristics. PLoS Genet 2008, 4:
e1000054.
23. Katoh M: Cancer genomics and genetics of FGFR2. Int J Oncol 2008,
33:233-237.
24. Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Haas C, Hudelist G,
Czerwenka K, Kubista E: Differential gene expression profile in breast
cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008,
110:273-281.
25. Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX,
Guan XY: Fibroblast growth factor receptor 2-positive fibroblasts provide
a suitable microenvironment for tumor development and progression in
esophageal carcinoma. Clin Cancer Res 2009, 15:4017-4027.
26. Garcia-Maya M, Anderson AA, Kendal CE, Kenny AV, Edwards-Ingram LC,
Holladay A, Saffell JL: Ligand concentration is a driver of divergent
signaling and pleiotropic cellular responses to FGF. J Cell Physiol 2006,
206:386-393.
27. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer
initiation and progression. Nature 2004, 432:332-337.
28. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
29. Mailleux AA, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N,
Kato S, Dickson C, Thiery JP, Bellusci S: Role of FGF10/FGFR2b signaling
during mammary gland development in the mouse embryo.
Development 2002, 129:53-60.
30. Parsa S, Ramasamy SK, De Langhe S, Gupte VV, Haigh JJ, Medina D,
Bellusci S: Terminal end bud maintenance in mammary gland is
dependent upon FGFR2b signaling. Dev Biol 2008, 317:121-131.
31. Abate-Shen C, Shen MM: FGF signaling in prostate tumorigenesis: new
insights into epithelial-stromal interactions. Cancer Cell 2007, 12:495-497.
Huijts et al. Breast Cancer Research 2011, 13:R72
http://breast-cancer-research.com/content/13/4/R72
Page 11 of 1232. Katoh M, Katoh M: FGFR2 and WDR11 are neighboring oncogene and
tumor suppressor gene on human chromosome 10q26. Int J Oncol 2003,
22:1155-1159.
33. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF,
Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ,
Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le
Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E,
Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T,
Hrafnkelsson J, et al: Common variants on chromosome 5p12 confer
susceptibility to estrogen receptor-positive breast cancer. Nat Genet
2008, 40:703-706.
34. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL:
Upregulation of basic fibroblast growth factor in breast carcinoma and
its relationship to vascular density, oestrogen receptor, epidermal
growth factor receptor and survival. Ann Oncol 1999, 10:707-713.
35. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P,
Lidereau R, Bieche I: Identification of novel genes that co-cluster with
estrogen receptor α in breast tumor biopsy specimens, using a large-
scale real-time reverse transcription-PCR approach. Endocr Relat Cancer
2006, 13:1109-1120.
36. Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T: Expression of
keratinocyte growth factor and its receptor in human breast cancer: its
inhibitory role in the induction of apoptosis possibly through the
overexpression of Bcl-2. Arch Histol Cytol 2004, 67:455-464.
37. Nomura S, Yoshitomi H, Takano S, Shida T, Kobayashi S, Ohtsuka M,
Kimura F, Shimizu H, Yoshidome H, Kato A, Miyazaki M: FGF10/FGFR2
signal induces cell migration and invasion in pancreatic cancer. Br J
Cancer 2008, 99:305-313.
38. Tsunoda S, Sakurai H, Saito Y, Ueno Y, Koizumi K, Saiki I: Massive T-
lymphocyte infiltration into the host stroma is essential for fibroblast
growth factor-2-promoted growth and metastasis of mammary tumors
via neovascular stability. Am J Pathol 2009, 174:671-683.
39. Theodorou V, Boer M, Weigelt B, Jonkers J, van der Valk M, Hilkens J: Fgf10
is an oncogene activated by MMTV insertional mutagenesis in mouse
mammary tumors and overexpressed in a subset of human breast
carcinomas. Oncogene 2004, 23:6047-6055.
40. Sorrell JM, Caplan AI: Fibroblasts: a diverse population at the center of it
all. Int Rev Cell Mol Biol 2009, 276:161-214.
41. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO:
Diversity, topographic differentiation, and positional memory in human
fibroblasts. Proc Natl Acad Sci USA 2002, 99:12877-12882.
42. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY: Anatomic
demarcation by positional variation in fibroblast gene expression
programs. PLoS Genet 2006, 2:e119.
43. Nolte SV, Xu W, Rennekampff HO, Rodemann HP: Diversity of fibroblasts: a
review on implications for skin tissue engineering. Cells Tissues Organs
2008, 187:165-176.
44. Huang GJ, Shifman S, Valdar W, Johannesson M, Yalcin B, Taylor MS,
Taylor JM, Mott R, Flint J: High resolution mapping of expression QTLs in
heterogeneous stock mice in multiple tissues. Genome Res 2009,
19:1133-1140.
45. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
doi:10.1186/bcr2917
Cite this article as: Huijts et al.: Allele-specific regulation of FGFR2
expression is cell type-dependent and may increase breast cancer risk
through a paracrine stimulus involving FGF10. Breast Cancer Research 2011
13:R72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huijts et al. Breast Cancer Research 2011, 13:R72
http://breast-cancer-research.com/content/13/4/R72
Page 12 of 12